PharmaMar Will Receive 21.1 Million to Build a Plant in Madrid and Research Rare Diseases

The aid received by Sylentis, from the European NextGenerationEU funds, will allow the development of the Syoligo project and involves the direct hiring of 86 new highly qualified positions and 350 indirect positions until 2030.

Sylentis, a PharmaMar Group company, has been selected to receive a €21.1 million grant for the construction of a new plant and research into rare diseases, the firm announced in a statement on Thursday, detailing that the grant will come from NextGenerationEU funds.

The entire grant received by Sylentis will go to the Syoligo project, which represents the first industrial deployment in Spain for the production of RNA-based drugs

Specifically, the entire grant received by Sylentis will be allocated to the Syoligo project, which represents the first industrial deployment in Spain for the production of RNA-based drugs , as well as the development of treatments for rare diseases. The new pharmaceutical plant, located in Getafe, Madrid, has a 6,000 square meter facility built under sustainability and digitalization criteria for maximum efficiency.

According to the company’s press release, the factory will have a dual purpose: to provide manufacturing services for Sylentis’ needs in its research projects for rare diseases , and to enter the business of third-party manufacturing of RNA-based drugs for use in various pathologies. Furthermore, the project will have a positive impact on the country, as it will boost employment with the direct hiring of 86 new highly qualified positions and 350 indirect positions by 2030.

The new pharmaceutical plant located in Getafe, Madrid, has an area of ​​6,000 square meters.
“Syoligo aims to establish the technological foundation necessary for the advancement of innovative therapies, as well as enable key facilities in Spain that enable sustainable growth and productivity. This project represents a fundamental strategic step in strengthening the European pharmaceutical industry,” commented Andreas Segerros, CEO of Sylentis.

__

(Featured image by Ousa Chea via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us